MedAvail Holdings, Inc. Common Stock
MDVL
MDVL was delisted on the 12th of February, 2024.
6 hedge funds and large institutions have $259K invested in MedAvail Holdings, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
14% less funds holding
Funds holding: 7 → 6 (-1)
49% less capital invested
Capital invested by funds: $505K → $259K (-$246K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.65K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$78.4K |
| 2 |
FPF
FNY Partners Fund
New York
|
-$1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1K |
MDVL Hedge Fund Activity: Q2 2017 in Review
6 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in MedAvail Holdings, Inc. Common Stock (MDVL) for Q2 2017, worth a combined $259K — down 49% from $505K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of MDVL and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Vanguard Group, adding an estimated $6.65K. The largest seller was Morgan Stanley, cutting an estimated $78.4K.
- 6 institutional investors held MedAvail Holdings, Inc. Common Stock (MDVL) as of Q2 2017, down from 7 in Q1 2017.
- Funds reported $259K of MedAvail Holdings, Inc. Common Stock stock for Q2 2017, down 49% quarter-over-quarter.
- 0 funds opened new MedAvail Holdings, Inc. Common Stock positions in Q2 2017 and 1 closed out, a net change of -1 holder.
- The largest MedAvail Holdings, Inc. Common Stock buyer in Q2 2017 was Vanguard Group, an estimated $6.65K added.
- The largest MedAvail Holdings, Inc. Common Stock seller in Q2 2017 was Morgan Stanley, an estimated $78.4K sold.
Based on aggregated 13F filings for Q2 2017.